CREB1 and liver cancer: Even though SGC-CBP30 hinders the transcriptional activity of CREB1 and has the potential to alleviate sorafenib resistance in mTOR-activated liver cancer, SGC-CBP30 is metabolized too quickly in vivo and might not be suitable for clinical application [51].